Log In
BCIQ
Print this Print this
 

CMV gB/MF59

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionVaccine consisting of recombinant human cytomegalovirus (CMV) glycoprotein B with MF59 adjuvant
Molecular Target Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/08/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today